PRPH.US ProPhase Labs Inc

Healthcare Pharmaceuticals USA Stocks
0.0058 USD
Close of Nov 17, 2026
0.0046 2.35
Market cap
USD 90.4K
P/E
-
P/B
0.37x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is PRPH.US undervalued?

Graham number

The Graham number of ProPhase Labs Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ProPhase Labs Inc fundamental analysis

No fundamental analysis for ProPhase Labs Inc yet.

ProPhase Labs Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ProPhase Labs Inc

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophage…

Full company profile